REGENERON PHARMACEUTICALS, INC. Restricted Cash, Current
REGENERON PHARMACEUTICALS, INC. (REGN) had Restricted Cash, Current of $10.20 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-07-30
- 2026-06-30: Restricted Cash, Current $10.20M.
- 2026-03-31: Restricted Cash, Current $8.00M.
- 2025-12-31: Restricted Cash, Current $5.60M.
- 2025-09-30: Restricted Cash, Current $6.70M.
| Period end | Restricted Cash, Current |
|---|---|
| 2026-06-30 | $10.20M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $8.00M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $5.60M 10-K · filed 2026-02-04 |
| 2025-09-30 | $6.70M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $19.80M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $2.80M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $800.00K 10-K · filed 2026-02-04 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 |
| 2024-06-30 | $7.50M 10-Q · filed 2025-08-01 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-04 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |